
3 Top Growth Stocks to Buy in the Second Half of 2025
Alibaba is a Chinese AI stock that's dirt cheap.
Meta Platforms is making a huge bet on AI that should pay off handsomely.
Vertex Pharmaceuticals is expanding into new indications.
10 stocks we like better than Vertex Pharmaceuticals ›
For decades, Jim McKay introduced ABC's Wide World of Sports with a memorable phrase, "The thrill of victory, and the agony of defeat." McKay's words could apply to many investors in the first half of this year. There have been periods of victory -- and periods of defeat.
Of course, the level of victory and defeat investors experienced depended on which stocks they owned. If you want greater chances of winning going forward, the stocks you pick will make a huge difference. Which stocks should you consider? Here are three top growth stocks to buy in the second half of 2025.
1. Alibaba Group Holding
Wall Street loves Alibaba Group Holding (NYSE: BABA). Of the 40 analysts surveyed by LSEG in July, 37 rated the stock as a "buy" or a "strong buy." The three outliers recommended holding Alibaba. The consensus 12-month price target reflects an upside potential of roughly 40%. I'm not always on the same page as Wall Street analysts, but I agree with the upbeat views about Alibaba.
For one thing, you can't even spell Alibaba without A and I. "Lbaba" just doesn't have the same ring to it. Alibaba is an artificial intelligence (AI) juggernaut in China. Its Alibaba Cloud unit commands 36% of the Chinese cloud infrastructure market, almost twice the market share of its nearest rival. Revenue from Alibaba Cloud's AI-related products has grown by triple-digit percentages for seven consecutive quarters.
The company also operates China's leading e-commerce platform. Alibaba's Taobao and Tmall online shopping sites continue to deliver solid revenue growth, and AI is helping improve the user experience on the platforms.
But the main reason I like Alibaba is its valuation. The stock trades at a forward earnings multiple of only 10.3. That's dirt cheap for a tech giant that raked in $137.3 billion in revenue and $17.4 billion in profits in its last fiscal year.
2. Meta Platforms
Meta Platforms (NASDAQ: META) could be an underappreciated leader in AI. It's not a pure-play AI company like OpenAI. It's not a cloud titan like Amazon (NASDAQ: AMZN), Microsoft (NASDAQ: MSFT), and Alphabet 's (NASDAQ: GOOG)(NASDAQ: GOOGL) Google. However, Meta is making a huge bet on AI that I suspect will pay off handsomely.
That wager is already paying off in some ways. For example, AI is helping Meta improve its recommendation models. The company has seen a 5% higher conversion rate on Reels in the latest quarter. Over the last six months, Meta's recommendation system improvements have led to a 7% increase in user time spent on Facebook and 6% on Instagram. More time on these social media apps translates to higher advertising revenue for Meta.
AI-powered business messaging presents a tremendous growth opportunity for the company. Businesses in developing nations such as Thailand and Vietnam use Meta's messaging apps heavily to communicate with customers. With AI, this model could be deployed in the U.S. and other major markets.
Perhaps the most intriguing arena for Meta, though, is in AI devices. The company is already a leader in smart glasses thanks to its Ray-Ban Meta AI glasses. Its Quest virtual reality headsets remain highly popular with users. I think Meta could be one of the biggest players in a potentially massive AI device market over the next few years.
3. Vertex Pharmaceuticals
Not every great growth stock that I recommend buying in the second half of 2025 is focused heavily on AI. Vertex Pharmaceuticals (NASDAQ: VRTX) is a drugmaker with terrific growth prospects.
So far in Vertex's history, cystic fibrosis (CF) has been the company's primary focus. That's worked out quite well for the big biotech innovator. Vertex markets the only therapies that treat the underlying cause of CF. Its latest CF drug, Alyftrek, offers the most convenient dosing in its lineup and will almost certainly become a blockbuster quickly.
However, Vertex has expanded its horizons to other therapeutic areas. Casgevy, the first approved CRISPR gene-editing therapy, targets two rare blood disorders -- sickle cell disease and transfusion-dependent beta-thalassemia. Earlier this year, Journavx became the first new class of pain medication approved by the U.S. Food and Drug Administration in more than two decades. As a powerful pain drug that isn't an opioid, I expect this new product will become another huge winner for Vertex.
And there are potentially more big winners on the way. Vertex's pipeline features three other drugs in late-stage clinical testing. Inaxaplin targets APOL1-mediated kidney disease. Povetacicept's first targeted indication is chronic kidney disease IgA nephropathy. Zimislicel holds the potential to cure severe type 1 diabetes. I like the chances of success for all three programs.
Should you invest $1,000 in Vertex Pharmaceuticals right now?
Before you buy stock in Vertex Pharmaceuticals, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Vertex Pharmaceuticals wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $687,149!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,060,406!*
Now, it's worth noting Stock Advisor's total average return is 1,069% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of July 15, 2025
John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool's board of directors. Keith Speights has positions in Alphabet, Amazon, Meta Platforms, Microsoft, and Vertex Pharmaceuticals. The Motley Fool has positions in and recommends Alphabet, Amazon, Meta Platforms, Microsoft, and Vertex Pharmaceuticals. The Motley Fool recommends Alibaba Group and recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Globe and Mail
28 minutes ago
- Globe and Mail
Shareholders Alert: Investigation Into Otis Worldwide Corporation (OTIS) - Contact Levi & Korsinsky to Protect Your Rights
New York, New York--(Newsfile Corp. - July 23, 2025) - Levi & Korsinsky notifies investors that it has commenced an investigation of Otis Worldwide Corporation ("Otis Worldwide Corporation") (NYSE: OTIS) concerning possible violations of federal securities laws. On July 23, 2025, Otis reported its second quarter fiscal 2025 earnings, unveiling net sales for the quarter of $3.6 billion that fell below analysts' expectations for $3.71 billion. Management noted that new-equipment sales declined 10%, worse than the market feared, in the quarter, triggering the company to reduce their annual guidance from $14.6 - $14.8 billion down to $14.5 - $14.6 billion in the second quarter. While the Company largely blamed the setback on challenges in China, in which new equipment sales fell 20% in the quarter, declines were also seen in the Americas and Asia Pacific. Following this news, Otis' stock price fell by $12.79 per share to open at $88.20 per share. To obtain additional information, go to: or contact Joseph E. Levi, Esq. either via email at jlevi@ or by telephone at (212)363-7500. WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes. To view the source version of this press release, please visit


Globe and Mail
28 minutes ago
- Globe and Mail
MORE® Lists Prime Duplex Investment Opportunity in South Los Angeles with Income and Redevelopment Upside
"MORE®" Turnkey modern duplex at 9128–9130 Menlo Ave provides solid rental income, with R2-1 zoning and TOC Tier 3 designation offering strong long-term redevelopment potential. MORE®, a leading commercial real estate brokerage, is proud to announce the exclusive listing of 9128–9130 Menlo Ave in South Los Angeles. This 2010-built duplex features two spacious 4-bedroom, 2-bathroom units totaling ±2,546 square feet, positioned on a ±5,203-square-foot lot. Move-in ready and fully detached, the property offers an ideal opportunity for owner-users, investors, or developers seeking income, flexibility, and long-term upside. Each unit has been recently upgraded with new flooring, carpet, fresh paint, water heaters, and in-unit laundry hookups. A long driveway leads to a detached 2-car garage with potential for ADU conversion, creating additional value for future development. Strategically located in an R2-1 zoned parcel within TOC Tier 3, the property benefits from favorable zoning for increased density and redevelopment. Its prime South LA location places it minutes from major attractions such as Sofi Stadium, Intuit Dome, USC, Downtown Los Angeles, and Exposition Park, offering excellent connectivity and sustained rental demand. 'This listing is a compelling blend of immediate income generation and long-term development potential,' said John Ha, Chief Executive Officer and Broker of MORE®. 'With modern construction, updated interiors, and a location at the center of South LA's transformation, 9128–9130 Menlo Ave is well-positioned for forward-thinking buyers.' With proximity to major freeways and some of LA's most dynamic entertainment, educational, and cultural hubs, this duplex represents a rare turnkey investment in one of the city's most rapidly evolving neighborhoods. For more information on available listings, investment opportunities, or to learn more about the firm's services, visit or contact MORE® directly at +1 424 666 8133. ABOUT MORE® MORE® is a leading Los Angeles-based commercial real estate brokerage specializing in investment sales, property management, leasing, and advisory services. With a proven track record of over $400 million in closed transactions, MORE® is committed to delivering tailored solutions that help investors, landlords, and developers achieve long-term success in one of the nation's most competitive and dynamic real estate markets.


Globe and Mail
28 minutes ago
- Globe and Mail
Wendy's Appoints Pete Suerken as U.S. President
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Wendy's ( (WEN)) has shared an update. On July 22, 2025, Wendy's announced the appointment of Pete Suerken as President, U.S., succeeding Abigail Pringle, who will depart the company after a transition period. Suerken, who has a strong background in supply chain management and innovation, is expected to drive profitability and growth for Wendy's U.S. operations. This leadership change aims to enhance Wendy's operational excellence and strategic priorities, benefiting franchisees, employees, and shareholders. The most recent analyst rating on (WEN) stock is a Hold with a $18.00 price target. To see the full list of analyst forecasts on Wendy's stock, see the WEN Stock Forecast page. Spark's Take on WEN Stock According to Spark, TipRanks' AI Analyst, WEN is a Neutral. The overall score is driven by stable financial performance and attractive valuation, offset by technical indicators suggesting bearish trends. Earnings call highlights mixed sentiment, with strategic growth plans facing near-term challenges, particularly in the U.S. market. To see Spark's full report on WEN stock, click here. More about Wendy's Wendy's, founded in 1969 by Dave Thomas in Columbus, Ohio, is a prominent player in the fast-food industry, known for its made-to-order square hamburgers, fresh salads, and signature items like chili and Frosty desserts. The company operates over 7,000 restaurants worldwide and is committed to quality and positive social impact, notably through the Dave Thomas Foundation for Adoption. Average Trading Volume: 6,082,004 Technical Sentiment Signal: Sell Current Market Cap: $2.01B See more insights into WEN stock on TipRanks' Stock Analysis page. Disclaimer & Disclosure Report an Issue